Search | Clinical Trials Finder

Conditions: Kidney Failure, Chronic
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Glendale, California • Orlando, Florida • Minneapolis, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: ADL5859, Naproxen, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more

Conditions: Systemic Lupus Erythematosus
Interventions: Matching placebo, Cenerimod; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Anniston, Alabama • Clearwater, Florida

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, Camlipixant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 112
States / cities: Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 91 more

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Conditions: Phosphomannomutase 2 Deficiency, PMM2-CDG
Interventions: GLM101 (Part A, Double-blind), Placebo (Part A, Double-blind), GLM101 (Part B, Open-label); Drug
Lead sponsor: Glycomine, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Idiopathic Hypersomnia
Interventions: ALKS 2680, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 34
States / cities: Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Asthma
Interventions: AZD8630, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 18
States / cities: Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more

Conditions: Atopic Dermatitis, Psoriasis
Interventions: YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily; Drug
Lead sponsor: Hangzhou Yirui Pharmaceutical Technology Co., Ltd; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Atopic Dermatitis
Interventions: 1.1% w/w AMTX-100 CF-part1, Placebo, 1.1% w/w AMTX-100 CF3-part2; Drug
Lead sponsor: Amytrx Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 11
States / cities: Cerritos, California • Encino, California • Long Beach, California + 8 more

Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions: REGN7999, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis
Interventions: RPT193, Placebo; Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 13
States / cities: Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more

Conditions: Alcohol Use Disorder
Interventions: CMND-100; Drug
Lead sponsor: Clearmind Medicine Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Baltimore, Maryland

Conditions: Autism Spectrum Disorder, Autistic Disorder, Autism, Asperger's Syndrome, Pervasive Development Disorders
Interventions: Folinic Acid and placebo, Folinic Acid; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 3 Years to 14 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Healthy Participants, Hemophilia A, Hemophilia B, Factor VII Deficiency
Interventions: SR604, Placebo; Drug
Lead sponsor: Equilibra Bioscience LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 9
States / cities: Glendale, California • Los Angeles, California • Chicago, Illinois + 6 more

Conditions: Rheumatoid Arthritis
Interventions: FB704A, Placebo; Drug
Lead sponsor: Fountain Biopharma Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: Dupilumab, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Year to 11 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 18 more

Conditions: Obesity, Overweight
Interventions: NNC0174-1213 A, Cagrilintide B, Placebo A (NNC0174 1213 A); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: San Antonio, Texas • Salt Lake City, Utah

Conditions: Osteoarthritis
Interventions: LNA043, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 11
States / cities: Phoenix, Arizona • La Mesa, California • Sacramento, California + 8 more

Conditions: Insomnia
Interventions: E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: New York, New York • Cincinnati, Ohio

Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions: Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177); Biological · Other · Drug
Lead sponsor: Beat AML, LLC; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more

Search by objective public record fields.

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

A Folinic Acid Intervention for Autism Spectrum Disorders

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)

Evaluate the Safety, Tolerability, Pharmacokinetics,and Clinical Activity of FB704A

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia